SiriusPoint Azioni (NYSE: SPNTpB) prezzo delle azioni, notizie, grafici, ricerca sulle azioni, profilo.

SiriusPoint (NYSE:SPNTpB) Azioni Citazioni e riassunti delle notizie

SiriusPoint Ltd provides property and casualty reinsurance coverage to insurance and reinsurance companies in the United States, Canada, Bermuda, the United Kingdom, and Europe. The company operates through two operating segments: Reinsurance and Insurance & Services. The company's product portfolio consists of reinsurance contracts for property insurance including both residential and commercial properties, workers' compensation, personal automobile, businesses' general liability insurance, professional liability insurance to protect professional advisors and service providers, agriculture insurance, and mortgage insurance. The majority of the revenue is generated from its Insurance & Services segment.

SiriusPoint Ltd. 8.00% Resettable Fixed Rate Preference Shares, Series B, $25.00 liquidation preference per share

SiriusPoint Ltd

Oppenheimer analyst Kristen Owen maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Outperform and raises the price target from $448 to $477.

News

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Deere, Raises Price Target to $477

Cantor Fitzgerald analyst Kristen Kluska reiterates Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) with a Overweight and maintains $11 price target.

Reiteration

CDXS

Cantor Fitzgerald Reiterates Overweight on Codexis, Maintains $11 Price Target

WIIM

LGTY

Logility Supply Chain Solutions shares are trading lower after the company reported worse-than-expected Q2 revenue results and issued FY25 revenue guidance below estimates.

Oppenheimer analyst Scott Schneeberger maintains Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Outperform and raises the price target from $712 to $722.

INTU

Oppenheimer Maintains Outperform on Intuit, Raises Price Target to $722

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) with a Overweight.

KROS

Cantor Fitzgerald Reiterates Overweight on Keros Therapeutics

Oppenheimer analyst Ittai Kidron maintains Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) with a Outperform and raises the price target from $125 to $140.

ESTC

Oppenheimer Maintains Outperform on Elastic, Raises Price Target to $140

The U.S. dollar surged to its highest level in over two years against a basket of currencies on Friday, extending its rally to an eighth consecutive week — the longest winning <a href="https://www.benzinga.com/markets/forex">streak in 14 months. </a>
A wave of weaker-than-expected business activity data from Europe has weighed heavily on the euro and the British pound, as investors brace for faster rate cuts by the European Central Bank (ECB) and the Bank of England (BoE).
<h3 class="wp-block-heading">Eurozone PMI Dives Into Contraction</h3>
In November, private-sector activity in the eurozone unexpectedly contracted, triggering fresh concerns about the region&#8217;s economic outlook. 
The Composite Purchasing Managers&#8217; Index (PMI), compiled by S&amp;P Global, fell to 48.1, well below the neutral 50 threshold and missing forecasts for an unchanged reading. This marks the first contraction in eurozone business activity since January.
The downturn was driven by a drop in new orders, higher input prices, and escalating political uncertainty. 
Chris Williamson, chief business economist at S&amp;P Global, commented: &#8220;The flash PMI survey data for November showed the eurozone economy falling back into contraction, as malaise spread from the struggling manufacturing sector to the larger services economy.&#8221;
<h3 class="wp-block-heading">UK Economy Also Contracts</h3>
Across the Channel, the UK also delivered a disappointing PMI reading. The Composite PMI fell to 49.9, a drop from the previous month's 51.8, and below market expectations of 51.7. 
This marks the first contraction in UK private-sector activity since October 2023. 
&#8220;The November PMI is indicative of the economy slipping into a modest decline, with GDP dropping at a 0.1% quarterly rate, but the loss of confidence hints at worse to come &#8211; including further job losses -unless sentiment revives,&#8221; Williamson said.
<h3 class="wp-block-heading">Dollar Index Climbs as Euro, Pound Tumble</h3>
The U.S. Dollar Index (DXY), a key measure of the greenback's performance which is closely tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), climbed above 107 — a level last seen on Nov. 18, 2022. 
The euro plunged to 1.04 against the dollar, its lowest level in two years. The pound fell to 1.25, on track for its eighth straight weekly loss — the longest losing streak since 1980.
On Friday, S&amp;P Global will release flash PMI data for the U.S. economy at 9.45 a.m. ET. Economists predict the Services PMI to edge higher from 55 to 55.2 in November, which would mark the strongest expansion since August.
Manufacturing momentum is also expected to improve from 48.5 to 48.8, albeit remaining in contractionary territory. 
<h3 class="wp-block-heading">Analysts: Euro Vulnerable Amid Weak Data And Geopolitical Risks</h3>
Forex analysts point to several catalysts for the euro's sharp decline. 
&#8220;The worsening of the Ukrainian crisis has opened up a phase of risk aversion, hitting the EUR and GBP,&#8221; said Luca Cigognini, a forex strategist at Intesa Sanpaolo.
Chris Turner, an analyst at ING Group, highlighted the technical significance of the euro's drop: &#8220;Today's release of softer-than-expected eurozone PMIs proved the catalyst for EUR/USD to break to the downside of its two-year trading range. Even though a near 7% drop in just two months is exceptionally rapid by historical standards, we remain confident in a lower EUR/USD trajectory. Support is limited, with the next key level around 1.0190/1.0200.&#8221;
BBVA analyst Alejandro Cuadrado echoed similar concerns, pointing out that additional downside pressure on the euro could arise from political instability in Germany, the outcome of the U.S. elections, and intensifying geopolitical risks. 
&#8220;The tense situation in Europe could worsen in the short term, and investors are clearly taking a cautious approach on the EUR,&#8221; he said.
Cuadrado's colleague, Michalis Onisiforou, shed light on Germany's economic struggles: &#8220;The collapse of Germany's coalition government and early elections mean there won't be any immediate fiscal response to alleviate the pessimism surrounding the domestic economy. Coupled with escalating risks in the Russo-Ukrainian war, Germany faces significant headwinds.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42124676/november-small-cap-surge-could-carry-into-decembers-santa-rally-historical-trends-suggest">November Small-Cap Surge Could Carry Into December&#8217;s Santa Rally, Historical Trends Suggest</a></li>
</ul>
Photo: Shutterstock

Eurozone

Currency ETFs

Forex

Econ #s

Economics

ETFs

PowerShares DB US Dollar Index Bullish Fund

Dollar Hits 2-Year High As European Recession Fears Hammer Euro, Pound

Barclays analyst Kannan Venkateshwar maintains Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) with a Equal-Weight and lowers the price target from $32 to $31.

Barclays Maintains Equal-Weight on Warner Music Gr, Lowers Price Target to $31

Barclays analyst Seth Sigman maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Overweight and raises the price target from $78 to $90.

Barclays Maintains Overweight on Walmart, Raises Price Target to $90

PMAX

Powell Max shares are trading higher after the company secured a $40 million equity line of credit with Yorkville Advisors to enhance liquidity and support strategic investments.

AMIX

Autonomix Medical shares are trading lower after the company announced the pricing of a $9 million underwritten public offering.

Barclays analyst Adrienne Yih maintains Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) with a Overweight and raises the price target from $31 to $32.

Barclays Maintains Overweight on Gap, Raises Price Target to $32

Powell Max Secures $40M Equity Line Of Credit With Yorkville Advisors To Enhance Liquidity Solutions And Support Strategic Investments

Boxing legend Floyd Mayweather Jr. is expanding his real estate empire with a major stake in 601W Companies&#8217; $10 billion office portfolio, marking his latest move in commercial property investment. According to The Real Deal, the deal, announced just weeks after his $402 million apartment portfolio acquisition, gives him partial ownership of 18 buildings totaling 10 million square feet.
Don't Miss:
<ul>
<li>During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
While specific financial terms remain confidential, a source close to the deal described it as Mayweather&#8217;s &#8220;most significant&#8221; investment. The former world champion, who has accumulated $1.1 billion in career earnings, previously invested over $100 million with office landlord SL Green.
The portfolio includes prominent properties like 410 10th Avenue in Hudson Yards, Chicago&#8217;s Aon Center and Old Post Office Building and the Harborside office complex in Jersey City. Mark Karasick, managing member of 601W, confirmed that Mayweather&#8217;s investment will support property repositioning efforts and new acquisitions. The firm seeks opportunities in distressed office properties across major metropolitan areas, including Chicago and New York.
According to the report, 601W Companies has successfully navigated post-pandemic challenges. At 410 10th Avenue, purchased for $952 million in late 2020, the property maintains sufficient rental income to cover its mortgage obligations through 2032 despite occupancy dropping to 65%<a href="https://www.benzinga.com/news/24/04/38475445/us-regulators-seize-republic-first-bancorp-fulton-bank-steps-in-as-buyer-amid-regional-banking-woes"> following First Republic Bank&#8217;s collapse</a>.
See Also: This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a>
The firm recently secured a $65 million loan on an $85 million Harborside property acquisition, reflecting continued lender confidence. While facing industrywide refinancing hurdles, 601W has successfully negotiated several workout arrangements, including a three-year extension on the Aon Center&#8217;s half-billion-dollar debt package and fresh equity injection for Chicago&#8217;s One South Wacker Drive.
&#8220;New York City is the center of the world,&#8221; Mayweather said in a statement. &#8220;A wise person once told me if you buy real estate in New York and hold on to it over the years, you will always make money and win.&#8221;
The investment follows Mayweather&#8217;s October agreement to purchase Black Spruce Management&#8217;s apartment portfolio, comprising over 60 rental buildings in what could become New York City&#8217;s largest real estate transaction of the year.
The <a href="https://www.benzinga.com/markets/24/10/41581902/boxing-great-floyd-money-mayweather-makes-400-million-investment-in-affordable-housing-portfolio">undefeated boxer&#8217;s expanding real estate portfolio</a> reflects growing investor interest in office properties despite persistent market uncertainty. His partnership with 601W Companies, known for trophy office ownership and redevelopment expertise, signals confidence in the sector&#8217;s post-pandemic recovery potential.
Read Next:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a></li>
</ul>
Image from Shutterstock

Real Estate

Mayweather Punches Into $10B Office Portfolio, Betting On Post-COVID Revival

With Five-Year Series A Warrants Exercisable At $6.54 Per Share

Offerings

Autonomix Medical Prices $9M Public Offering Of Common Stock And Pre-Funded Warrant Units At $6.54 Per Unit

Barclays analyst Alex Scott maintains Reinsurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) with a Overweight and raises the price target from $250 to $255.

Barclays Maintains Overweight on Reinsurance Gr, Raises Price Target to $255

Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) saw its shares rise on Friday<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> in the premarket session.</a>
Today, the company announced results from a Dose Range Finding (DRF) study for Probudur,<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42136987/virpax-announces-positive-results-for-the-swine-model-dose-range-finding-study-for-probudur" rel="noreferrer noopener"> its long-acting liposomal bupivacaine formulation.</a>
The study, conducted in minipigs, demonstrated that Probudur was well-tolerated with no adverse effects, supporting its potential for both immediate and extended pain relief. The DRF study was conducted to evaluate the tolerance of Probudur in an incisional wound healing model in minipigs. Probudur was injected locally into the tissue surrounding the incision area.
&#8220;The completion of these studies brings us another step closer to filing our Investigational New Drug Application (IND) for Probudur,&#8221; stated Jatinder Dhaliwal, Chief Executive Officer of Virpax.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, VRPX stock has lost over 88% in the past year.
Also Read:<a target="_blank" href="https://www.benzinga.com/24/11/42133364/us-stocks-on-edge-but-likely-to-end-the-week-in-the-green-trumps-treasury-pick-in-focus-expert-says-case-for-fed-pause-in-december-getting-stronger" rel="noreferrer noopener"> US Stocks Set To Open Lower On Friday As Investors Eye Cyclical Stocks: Trump&#8217;s Treasury Pick In Focus, Expert Says Case For Fed Pause In December &#8216;Getting Stronger&#8217;</a>
Yesterday, the company announced the extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
This collaboration will continue the development of Virpax&#8217;s promising product candidate, NES100, an intranasal peptide designed for the management of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42123188/virpax-announces-agreement-with-the-u-s-department-of-health-and-human-services-for-the-developmen" rel="noreferrer noopener">acute and chronic non-cancer pain.</a>
NES100 is a novel enkephalin-based drug, utilizing advanced nanotechnology to enhance delivery into the brain.
Enkephalin, a naturally occurring peptide, has pain-relieving properties but is difficult to administer effectively in its original form. Virpax&#8217;s proprietary Molecular Envelope Technology (MET) protects and facilitates the drug&#8217;s delivery through the olfactory nerve pathway to the brain, where it targets delta opioid receptors to suppress pain.
Notably, NES100 has shown promise in animal models without the risks of opioid tolerance, withdrawal, or addiction.
Jatinder Dhaliwal, CEO of Virpax, emphasized that the collaboration will aid Virpax in advancing NES100 through preclinical and clinical stages, potentially offering a safer alternative to opioids for managing pain.
This development marks an important step in Virpax&#8217;s strategy to address pain management while mitigating opioid-related risks, Dhaliwal highlighted.
Price Action: VRPX shares are trading higher by 55.7% to $0.9181 premarket at last check Friday.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42136530/whats-going-on-with-ehang-stock-today" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With EHang Stock Today?</a></li>
</ul>

Equities

Markets

Movers

General

VRPX

Why Is Virpax Pharmaceuticals Stock Gaining On Friday?

Oppenheimer analyst Ian Zaffino maintains Kyndryl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) with a Outperform and raises the price target from $33 to $37.

Oppenheimer Maintains Outperform on Kyndryl Hldgs, Raises Price Target to $37

Barclays analyst Saket Kalia maintains Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) with a Equal-Weight and raises the price target from $66 to $78.

PCOR

Barclays Maintains Equal-Weight on Procore Technologies, Raises Price Target to $78

Barclays analyst Tim Long maintains NetApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) with a Equal-Weight and raises the price target from $119 to $132.

NTAP

Barclays Maintains Equal-Weight on NetApp, Raises Price Target to $132

SiriusPoint

Learn About Cryptocurrency

acf/sidebar-related-posts

Learn about this leading blockchain platform that supports decentralized applications and smart contracts.

What is Ethereum?

Earning interest on your Ethereum is a great way to grow your cryptocurrency holdings. Find out how to earn interest on your Ethereum in 4 easy steps.

How to Earn Interest on Ethereum

Looking to invest in crypto? Discover the best crypto to invest in with our guide, featuring top picks and expert insights to maximize your returns.

10 Best Cryptocurrencies to Invest In for November 2024

10 Best Cryptocurrencies to Invest in for November 2024

Discover the best altcoins to invest in for high potential returns. Our top altcoin picks include Ethereum, Solana, Ripple, Dogecoin, Toncoin.

Top 10 Best Altcoins • Benzinga Crypto

10 Best Altcoins in November 2024

Top Cryptocurrency News

acf/news-feed

Cryptocurrency

$ARB

$BTC

$DOGE

$ETH

$SHIB

$SOL

$STRK

Bitcoin, Ethereum, Dogecoin Prep For Early Thanksgiving: 'BTC Is Currently (Less Than) One ETH Away From $100,000,' Says Trader

SHIB Coin Forming A 'Bull Flag'? This Could Be The Price Target If Shiba Inu Breaks Out

Short Sellers

Short Ideas

Trading Ideas

MSTR

Short Seller Andrew Left Targets MicroStrategy Stock As Hedge Against Bullish Bitcoin Bet: 'Completely Detached From BTC Fundamentals'

$AVAX

$PEPE

$SUI

'Dogecoin Millionaire' Shares $50 Million Meme Coin Strategy For 2025: Pepe, Brett Are This Bull Run's DOGE, Shiba Inu

Analyst Color

Bitcoin Analyst Warns Of '4-6 Flash Crashes' Before Year-End As It Inches Closer To $100K: That's The Moment Altcoins 'Shoot Off'

Aperto	-
Chiuso	-
Volume / Media	0 / 21.29K
Intervallo giornaliero	- - -
Intervallo a 52 settimane	24.60 - 25.74
Capitalizzazione di mercato	-
Rapporto P/E	-
Rendimento del dividendo	7.90%
Exchange	NYSE
RSI	0
Vendite allo scoperto	-
Periodo di copertura	-

Aperto	-
Chiuso	-
Volume / Media	0 / 21.29K
Intervallo giornaliero	- - -
Intervallo a 52 settimane	24.60 - 25.74
Capitalizzazione di mercato	-
Rapporto P/E	-
Rendimento del dividendo	7.90%
Exchange	NYSE
RSI	0
Vendite allo scoperto	-
Periodo di copertura	-

Comments

SiriusPoint

SiriusPoint (SPNTpB) Previsione

SiriusPoint (NYSE:SPNTpB) Azioni Citazioni e riassunti delle notizie

Notizie recenti

Dati finanziari

Confronta

FAQ

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Nome

Ricavi Variazioni
Lordo Variazioni
EBITDA Variazioni
EBIT Variazioni
Utili Variazioni